Kura Oncology Announces Positive Phase 1a/1b Trial Results

Kura Oncology ( (KURA) ) has shared an update.

On June 12, 2025, Kura Oncology and Kyowa Kirin announced positive results from the KOMET-007 Phase 1a/1b trial of ziftomenib in combination with standard chemotherapy for newly diagnosed AML patients with NPM1-m and KMT2A-r mutations. The trial demonstrated high rates of complete remission and minimal residual disease negativity, with a favorable safety profile. This development positions Kura Oncology to advance to Phase 3 studies, potentially impacting its market position and offering new hope for AML patients.

The most recent analyst rating on (KURA) stock is a Buy with a $32.00 price target. To see the full list of analyst forecasts on Kura Oncology stock, see the KURA Stock Forecast page.

Spark’s Take on KURA Stock

According to Spark, TipRanks’ AI Analyst, KURA is a Neutral.

Kura Oncology faces challenges typical of biotech firms in transition, with positive revenue growth yet struggling profitability. Significant milestones in drug applications and a strong cash position are positive, but technical indicators and valuation metrics present caution. The company’s stock performance reflects these mixed factors.

To see Spark’s full report on KURA stock, click here.

More about Kura Oncology

Kura Oncology, Inc. operates in the biotechnology industry, focusing on the development of innovative therapies for cancer treatment. The company’s primary product is ziftomenib, an investigational menin inhibitor targeting acute myeloid leukemia (AML), particularly in patients with specific genetic mutations such as NPM1-m and KMT2A-r.

Average Trading Volume: 1,284,983

Technical Sentiment Signal: Sell

Current Market Cap: $561.9M

For an in-depth examination of KURA stock, go to TipRanks’ Overview page.